Survival Analysis of Ovarian Carcinoma Patients in Clinical Trials

Abstract
This report provides a comprehensive assessment of the survival outcomes of patients with ovarian carcinoma who were enrolled in clinical trials. Ovarian carcinoma is a particularly deadly and aggressive type of cancer, so better treatment approaches require an in-depth understanding of patient survival trends. We analyzed survival outcomes of these patients and explored any potential differences in survival by treatment type.
Keywords: *survival analysis, ovarian carcinoma, log-rank, Kaplan-Meier, treatment efficacy*

Introduction
The Kaplan-Meier estimator estimates and plots survival probability as a function of time using a non-parametric approach. We utilized the Ovarian dataset, which consists of clinical data from 26 ovarian carcinoma patients for our analysis. The dataset includes information such as patient age, treatment type, and survival status. The time to an event, more specifically the time to death or censoring, was the main endpoint of interest.

Results
The fig alongside displays the survival curve with confidence interval for the two treatment groups, "rx=1" (cyclophosphamide) and "rx=2" (cyclophosphamide and adriamycin combined). The survival curve for group 1, shows a gradual decrease over time, with an estimated survival probability of 43.1% at 20.97 months. The survival curve for group 2 on the other hand exhibits a slightly better outcome, with an estimated survival probability of 56.4% at 18.5 months.



Furthermore, we performed log-rank test to determine whether the difference in survival between the two treatment groups was statistically significant. The log-rank test resulted in a chi-square statistic of 1.1 with one degree of freedom for our analysis ($p = 0.3$). The results from the log-rank test did not reveal a significant difference in survival between the treatment types (rx=1 and rx=2) for ovarian carcinoma patients in the clinical trials.

Conclusion
This study analyzed the survival outcomes of ovarian cancer patients in clinical trials, focusing on the impact of different treatment options. The results indicate that combined treatment with cyclophosphamide and adriamycin may slightly improve survival outcomes compared to cyclophosphamide alone, despite the fact that no significant difference was found between the treatment groups. However, more thorough research and larger sample sizes might be required to offer more conclusive evidence. Overall, this project emphasizes the value of survival analysis for patients with ovarian carcinoma in clinical trials.